ArticleMolecular biology reports2026
Mucopolysaccharidosis type II in tunisian families: IDS gene variations disrupting substrate binding and a novel deep intronic deletion reducing IDS expression.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) deficiency, leading to the accumulation of dermatan sulfate and heparan sulfate. This study aimed to investigate the molecular defects underlying MPS II in tP2ee unrelated Tunisian patients.
methodsThe IDS gene was analyzed by direct DNA sequencing. The functional consequence of a large intronic deletion was assessed by quantitative real-time PCR. Structural and functional impacts of missense variants were evaluated using 3D modeling with Swiss-PdbViewer and PyMOL.
resultsThree distinct mutations were identified. Two patients (P1 and P2) with severe phenotypes were hemizygous for the missense variants p.R88P and p.H138Y. A third patient P3 carried a novel 1310-pb intronic deletion associated with significantly reduced IDS transcript levels, suggesting impaired splicing or transcript stability. The identified variant was described according to HGVS nomenclature as NC_000023.11:g.149501061_149502370del, corresponding to a 1310 deep intronic deletion within intron 3 of the IDS. Structural analysis indicated that both missense mutations induce conformational alterations affecting the substrate-binding region. The p.H138Y substitution modifies the local chemical environment near the catalytic pocket, potentially impairing substrate interaction and enzymatic activity. In contrast, the p.R88P variant introduces structural constraints that disrupt local folding and destabilize interactions, indirectly affecting the positioning of the catalytic formylglycine residue. Moreover, we identified a large number of single-nucleotide sequence variants in hemizygous status in patient P3.
conclusionThis study identifies a novel deep intronic deletion in the IDS gene and highlights the structural and functional impact of missense mutations in Tunisian MPS II patients. These findings expand the mutational spectrum of IDS and improve understanding of genotype-phenotype correlations, contributing to accurate molecular diagnosis.
Indexed as
Identifiers
42489956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.